Home » Newsletters » BioWorld Science

BioWorld Science

June 30, 2021

View Archived Issues

Cybin reports preclinical data on deuteration modifications in psychedelic molecules

Wigen Biomedicine Technology presents new Aurora kinase inhibitors

Shenzhen Salubris Pharmaceuticals patents factor XIa inhibitors

Shanghai Yingli Pharmaceutical describes new GTPase KRAS inhibitors

Medshine Discovery identifies new ERK-2 inhibitors

Henan Zhiwei Biomedicine, Henan Normal University patent Bruton tyrosine kinase inhibitors

Antitumor activity of novel prodrug TRN-000546

mGluR2 ago-PAM [18F]mG2P026 shows in vivo promise as a PET-imaging ligand

Loss-of-function mutations in IPO8 lead to syndromic thoracic aortic aneurysm

A dimeric LAIR-2 Fc fusion protein targets tumor ECM and promotes T-cell function by blocking LAIR-1

Encouraging phase II results seen with bomedemstat in essential thrombocythemia, myelofibrosis

Iovance provides clinical data for LN-145 in mNSCLC

Teneurin-4 identified as potential target and biomarker for triple negative breast cancer

First patient dosed in phase I/IIa trial of PRL-02 in metastatic prostate cancer

Positive phase Ib data reported for CVL-231 in patients with schizophrenia

Ori-CAR-001 CAR T-cell therapy targeting glypican-3 safe in phase I study

Initial phase I data for VBI-2902a, an enveloped virus-like particle COVID-19 vaccine candidate

FDA clears IND application for CLN-619 for the treatment of solid tumors

Elicio initiates phase I/II AMPLIFY-201 study of ELI-002 in KRAS-driven cancers

Trial finds rice-based oral cholera vaccine safe, effective

Dosing begins in phase Ib/II study of TTI-621 with doxorubicin in leiomyosarcoma

Novel miRNAs found with prognostic value in heart failure

Altimmune discontinues AdCOVID development, updates T-COVID progress

Endpoints not met in phase II trial of ANG-3777 in COVID-19-associated pneumonia

FDA approves IND for phase I/II trial of ExoFlo for mild to moderate COVID-19

HZN-7734 enters phase II study for SLE

Alnylam initiates phase II study of zilebesiran for mild to moderate hypertension

Saniona begins phase I trial of SAN-711 for neuropathic disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...